5-(1-Benzothiophen-2-yl)furan-2-carbaldehyde

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5-(1-Benzothiophen-2-yl)furan-2-carbaldehyde
• 化学式: C₁₃H₈O₂S
• 分子量: 228.271
• InChiKey: IPBRDLJFHQZKFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴-2-呋喃甲醛 、 苯并噻吩-2-硼酸 在 palladium diacetate 四丁基溴化铵 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 2.0h， 以61%的产率得到5-(1-Benzothiophen-2-yl)furan-2-carbaldehyde
  参考文献：
  名称：

  Preparation of 5-Aryl Furfurals and Aryl Thiophene-2-carboxaldehydes via Palladium-Catalyzed C−C Bond Formation in Aqueous Media¹

  摘要：

  [GRAPHICS]A series of 5-aryl furfurals and aryl thiophene-2-carboxaldehydes was synthesized. To this end, efficient and effective palladium-catalyzed C-C bond-forming reactions were carried out at room temperature in aqueous media. This mild process allowed the cross-coupling reaction of the bromides to occur in the presence of electrophilic functional groups, which is a valuable advantage over previously reported methods.

  DOI：

  10.1021/ol990708m

文献信息

• Thrombopoietin mimetics
  申请人：——

  公开号：US20030083361A1

  公开（公告）日：2003-05-01

  Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted naphthimidazole derivative.

  发明了非肽类TPO类似物。还发明了一种治疗血小板减少症的方法，包括在需要的哺乳动物，包括人类中，向该哺乳动物施用所选取代萘咪唑衍生物的有效量。
• CYANOTRIAZOLE COMPOUNDS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20160229816A1

  公开（公告）日：2016-08-11

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中有定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖症的副作用较小，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖症具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、脂肪肝、动脉粥样硬化和/或心血管疾病，以及那些从刺激能量消耗中受益的疾病或疾病。
• Mono and Dinuclear Palladium Pincer Complexes of NNSe Ligand as a Catalyst for Decarboxylative Direct C−H Heteroarylation of (Hetero)arenes
  作者：Sohan Singh、Vikki N. Shinde、Sunil Kumar、Neha Meena、Nattamai Bhuvanesh、Krishnan Rangan、Anil Kumar、Hemant Joshi

  DOI：10.1002/asia.202300628

  日期：2023.10.4

  NNSe pincer ligand and its palladium pincer complexes. Surprisingly, the reactivity of the ligand toward the palladium precursor is base-dependent. In the presence of the Et3N base, a mononuclear pincer complex was formed whereas in the absence of a base, a dinuclear pincer complex was formed. The complexes were used as catalysts for decarboxylative direct C−H heteroarylation of (hetero)arenes. Among

  本报告描述了新型 NNSe 钳形配体及其钯钳形配合物的合成。令人惊讶的是，配体对钯前体的反应性是碱依赖性的。在存在Et 3 N碱基的情况下，形成单核钳复合物，而在不存在碱基的情况下，形成双核钳复合物。该配合物用作（杂）芳烃脱羧直接 C−H 杂芳基化的催化剂。在这些配合物中，发现双核配合物更具反应性。只需 2.5 mol% 的催化剂负载即可激活广泛的底物范围。
• Cyanotriazole compounds
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US10626095B2

  公开（公告）日：2020-04-21

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰三唑化合物： 其中各符号在说明书中定义，或其盐。该化合物或其盐可刺激柠檬酸循环活性和/或改善高血糖，且副作用小、安全性高，因此可用于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或紊乱、例如，糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、肝脂肪变性、动脉粥样硬化和/或心血管疾病，以及可从刺激能量消耗中获益的疾病或紊乱。
• THROMBOPOIETIN MIMETICS
  申请人：SmithKline Beecham Corporation

  公开号：EP1244446A1

  公开（公告）日：2002-10-02